Fulcrum Neuroscience is developing new therapeutics to treat neurodegenerative conditions such as Alzheimer’s Disease (AD).

Our researchers recently formulated a unified hypothesis of AD identifying brain cholesterol processing as a key driver of disease progression (pre-print manuscript here).

The Fulcrum Neuroscience platform enables a new approach to neurodegenerative disease drug discovery. We are generating deep insights into disease pathology and variability in diverse populations. Our work is driving novel biomarker characterization and innovative strategies for stabilizing brain energy metabolism, including new drugs.

At the heart of the Fulcrum platform is a computer model of Brain Health and Neurodegeneration coupled with a digital twin generator. Digital twins can be used to simulate whole populations, to analyze how new drugs may behave in a clinical trial, or to simulate an individual’s risk of disease and how best to prevent or treat it.

Digital twin analysis provides tangible, explainable insights that help researchers and physicians increase the likelihood of additional years of cognitive health, enhancing quality of life, reducing family caregiving burdens and reducing total medical costs.

We won’t stop until we live in a world without cognitive decline.